Natural, chimeric and hybrid glycosaminoglycan polymers and methods of making and using same

Abstract

The present invention relates to methodology for polymer grafting by a polysaccharide synthase and, more particularly, polymer grafting using the hyaluronate or chondroitin or heparin / heparosan synthases from Pasteurella multocida, in order to create a variety of glycosaminoglycan oligosaccharides having a natural or chimeric or hybrid sugar structure.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims benefit under 35 U.S.C. 119(e) of U.S. Provisional No. 60 / 305,263, filed Jul. 13, 2001, entitled “NANO HYALURONIC ACID AND METHODS OF MAKING AND USING SAME,” the contents of which is expressly incorporated herein in its entirety by reference. [0002] This application is a continuation-in-part of copending U.S. Ser. No. 09 / 437,277, filed Nov. 11, 1999, entitled “POLYMER GRAFTING BY POLYSACCHARIDE SYNTHASES,” which claims benefit under 35 U.S.C. 119(e) of U.S. Provisional No. 60 / 107,929, filed Nov. 11, 1998, entitled “POLYMER GRAFTING BY POLYSACCHARIDE SYNTHASES,” the contents of both of which are expressly incorporated herein in their entirety by reference. [0003] This application is also a continuation-in-part of copending U.S. Ser. No. 09 / 283,402, filed Apr. 1, 1999, entitled “DNA ENCODING HYALURONAN SYNTHASE FROM PASTEURELLA MULTOCIDA AND METHODS;” which claims benefit under 35 U.S.C. 119(e) of U.S. Provisional ...

AI Technical Summary

Benefits of technology

[0036] The present invention encompasses methods of producing a variety of unique biocompatible molecules and coatings based on polysaccharides. Polysaccharides, especially those of the glycosaminoglycan class, serve numerous roles in the body as structural elements and signaling molecules. By grafting or making hybrid molecules composed of more than one polymer backbone, it is possible to meld distinct physical and biological properties into a single molecule without resorting to unnatural chemical reactions or residues. The present invention also incorporates the propensity of certain recombinant enzymes, when prepared in a virgin state, to utilize various acceptor molecules as the seed for further polymer growth: naturally occurring forms of the enzyme or existing living wild-type host organisms do not display this ability. Thus, the present invention results in (a) the production of hybrid oligosaccharides or polysaccharides and (b) the formation of polysaccharide coatings. Such hybrid polymers can serve as “molecular glue”—i.e. when two cell types or other biomaterials interact with each half of a hybrid molecule, then each of the two phases are bridged.

[0038] Recombinant pmHAS, pmCS, pmHS, and PgIA elongate exogenous functional oligosaccharide acceptors to form long or short polymers in vitro; thus far no other Class I HA synthase has displayed this capability. The directionality of synthesis was established definitively by testing the ability of pmHAS and pmCS and pmHS and PgIA to elongate defined oligosaccharide derivatives. The non-reducing end sugar addition allows the reducing end to be modified for other purposes; the addition of GAG chains to small molecules, polymers, or surfaces is thus readily performed. Analysis of the initial stages of synthesis demonstrated that pmHAS and pmCS and pmHS and PgIA added single monosaccharide units sequentially. Apparently the fidelity of the individual sugar transfer reactions is sufficient to generate the authentic repeating structure of HA or chondroitin or heparin. Therefore, simultaneous addition of disaccharide block units is not required as hypothesized in some recent models of polysaccharide biosynthesis. pmHAS and pmCS and pmHS and PgIA appear distinct from most other known HA and chondroitin and heparin syntheses based on differences in sequence, topology in the membrane, and / or putative reaction mechanism.

[0043] HA oligosaccharide treatment of cancer cell lines in culture reduces their rate of proliferation. HA oligosaccharides are also very promising in an in vivo assay for tumor growth and metastasis. In the reported assay, mice were injected with an invasive and virulent tumor cell line, and the progression of disease (e.g. general health, number of tumors, size of tumors) was monitored at a 10 day timepoint. Treatment with HA oligosaccharides greatly reduced the number and the size of tumors. Untreated animals required euthanasia within 2-4 weeks because of tremendous tumor growth. Various cancer cell lines, including melanoma, glioma, carcinomas from lung, breast and ovary, are susceptible to the therapeutic action of HA oligosaccharides.

Problems solved by technology

In general, these membrane-bound synthase proteins are difficult to manipulate by typical procedures, and only a few enzymes have been identified after biochemical purification.

Despite this sequence information, the molecular details concerning the three-dimensional native structures, the active sites, and the mechanisms of catalytic action of the polysaccharide syntheses, in general, are very limited or absent.

However, the synthetic control and the reproducibility of large-scale reactions are not always successful.

Additionally, such polysaccharides are only available having a large molecular weight distribution, and oligosaccharides of the same repeat units are not available.

The latter two methods are often restricted by the specificity and the properties of the available naturally occurring enzymes.

Many of these enzymes are neither particularly abundant nor stable but are almost always expensive.

Unfortunately, many of the physical and biological properties of polysaccharides do not become apparent until the polymer contains 25, 100, or even thousands of monomers.

Images